Spongiacidin A

Spongiacidin A

SCHEMBL23938900

NC1NC(=O)/C(=C2/CCNC(=O)c3[nH]c(Br)c(Br)c32)N1

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 9/20 0.56
CDK5R1 Q15078 9/20 0.56
CCNB2 O95067 6/20 0.55
CDK1 P06493 6/20 0.55
CCNB1 P14635 6/20 0.55
CCNB3 Q8WWL7 6/20 0.55
CDK4 P11802 3/20 0.55
ERBB2 P04626 2/20 0.55
CHEK1 O14757 2/20 0.55
PARP16 Q8N5Y8 1/20 0.35
PARP3 Q9Y6F1 1/20 0.35
RAF1 P04049 4/20 0.34
MAPK1 P28482 4/20 0.34
MAP2K1 Q02750 4/20 0.34
PRKD3 O94806 2/20 0.34
PRKCG P05129 2/20 0.34
PRKCB P05771 2/20 0.34
PRKCA P17252 2/20 0.34
PRKCH P24723 2/20 0.34
PRKCI P41743 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3987882 0.75 CDK5 (0.63) CDK5CDK5R1CCNB2CDK1CCNB1
SCHEMBL15426067 0.74 CDK5 (0.73) CDK5CDK5R1CCNB2CDK1CCNB1
SCHEMBL3424550 0.72 CDK5 (0.55) CDK5CDK5R1CCNB2CDK1CCNB1
SCHEMBL3425853 0.67 CDK5 (0.57) CDK5CDK5R1CCNB2CDK1CCNB1
SCHEMBL3425857 0.67 CDK5 (0.57) CDK5CDK5R1CCNB2CDK1CCNB1
SCHEMBL3426570 0.66 CDK5 (0.77) CDK5CDK5R1CCNB2CDK1CCNB1
SCHEMBL3426574 0.66 CDK5 (0.77) CDK5CDK5R1CCNB2CDK1CCNB1
SCHEMBL13341095 0.66 CDK5 (0.77) CDK5CDK5R1CCNB2CDK1CCNB1
SCHEMBL17166885 0.63 CDK5 (0.57) CDK5CDK5R1CCNB2CDK1CCNB1
SCHEMBL3424813 0.58 CDK5 (0.67) CDK5CDK5R1CCNB2CDK1CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3515559-B1 COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF AML USING USP10 BIOMARKERS AND MODULATORS DANA FARBER CANCER INST INC (US) 2025-05-21 EP disclosed
US-20210324478-A1 COMPOSITIONS AND METHODS FOR IDENTIFICATION ASSESSMENT, PREVENTION, AND TREATMENT OF EWING SARCOMA USING TP53 DEPENDENCY BIOMARKERS AND MODULATORS DANA-FARBER CANCER INSTITUTE, INC. 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210324478-A1 COMPOSITIONS AND METHODS FOR IDENTIFICATION ASSESSMENT, PREVENTION, AND TREATMENT OF EWING SARCOMA USING TP53 DEPENDENCY BIOMARKERS AND MODULATORS TP53, MDM4, EWSR1 CDK5 673/4885CDK5R1 868/4885CCNB2 2270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.